**FOI 9279 - Drugs**

Issued September 2024

**Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:**

· **Abatacept [Orencia]**

· **Adalimumab [Humira]**

· **Adalimumab Biosimilars**

· **Apremilast [Otezla]**

· **Baricitinib [Olumiant]**

· **Bimekizumab [Bimzelx]**

· **Certolizumab [Cimzia]**

· **Etanercept [Enbrel]**

· **Etanercept Biosimilars**

· **Filgotinib [Jyseleca]**

· **Golimumab [Simponi]**

· **Guselkumab [Tremfya]**

· **Infliximab [Remicade]**

· **Infliximab Biosimilars**

· **Ixekizumab [Taltz]**

· **Risankizumab [Skyrizi]**

· **Rituximab [MabThera]**

· **Rituximab Biosimilars**

· **Sarilumab [Kevzara]**

· **Secukinumab [Cosentyx]**

· **Tocilizumab [Ro Actemra]**

· **Tocilizumab Biosimilars**

· **Tofacitinib [Xeljanz]**

· **Upadacitinib [Rinvoq]**

· **Ustekinumab [Stelara]**

· **Ustekinumab Biosimilar**

 Please see below data held by the Trust’s Pharmacy department for the Rheumatology department.

|  |  |
| --- | --- |
| ABATACEPT | 148 |
| ADALIMUMAB | 449 |
| APREMILAST | 8 |
| BARICITINIB | 34 |
| BIMEKIZUMAB | <5 |
| CERTOLIZUMAB | 19 |
| ETANERCEPT | 401 |
| FILGOTINIB | <5 |
| GOLIMUMAB | 88 |
| INFLIXIMAB | 45 |
| IXEKIZUMAB | <5 |
| RITUXIMAB | 23 |
| TOCILIZUMAB | 126 |
| TOFACITINIB | <5 |
| UPADACITINIB | 45 |
| USTEKINUMAB | 16 |